Cosmo NVLTS:0RGI +2.01%79 PB Ratio is 2.51 as of Jul. 05, 2026, which is 9% below its 10-year median of 2.77. GuruFocus rates LTS:0RGI with a GF Score™ of 79/100 and a GF Value™ of CHF42.53 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 920 Drug Manufacturers companies, Cosmo NV ranks worse than 62.07% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-07-05), Cosmo NV's share price is CHF69.71935. Cosmo NV's Book Value per Share for the quarter that ended in Dec. 2025 was CHF27.80. Hence, Cosmo NV's PB Ratio of today is 2.51.
The historical rank and industry rank for Cosmo NV's PB Ratio or its related term are showing as below:
LTS:0RGI'
s PB Ratio Range Over the Past 10 Years
Min: 1.22 Med: 2.77 Max: 5.87
Current: 2.54
During the past 13 years, Cosmo NV's highest PB Ratio was 5.87. The lowest was 1.22. And the median was 2.77.
LTS:0RGI's PB Ratio is ranked worse than 62.07% of 920
companies
in the Drug Manufacturers industry
Industry Median: 1.92
vs LTS:0RGI: 2.54
During the past 12 months, Cosmo NV's average Book Value Per Share Growth Rate was -4.30% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 0.10% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -2.20% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was -2.30% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Cosmo NV was 132.10% per year. The lowest was -8.00% per year. And the median was 6.30% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Cosmo NV PB Ratio Related Terms
Cosmo NV PB Ratio Historical Data
* Premium members only.
The historical data trend for Cosmo NV's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Cosmo NV's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cosmo NV PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cosmo NV's PB Ratio distribution charts can be found below:
* The bar in red indicates where Cosmo NV's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Cosmo NV's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Cosmo NV (LTS:0RGI) has a PB Ratio of 2.51 as of Jul. 05, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Cosmo NV and its competitors. This is near median its historical median of 2.77. Over the past decade, Cosmo NV's PB Ratio has ranged from 1.22 to 5.87. According to the industry distribution chart, Cosmo NV ranks #571 out of 920 companies in the Drug Manufacturers industry, placing it in the top 62.1%.
Is Cosmo NV's PB Ratio too high?
Cosmo NV's current PB Ratio of 2.51 is near median its 10-year median of 2.77. Over the past 10 years, this metric has ranged from a low of 1.22 to a high of 5.87. The Drug Manufacturers industry median PB Ratio is 1.92. Cosmo NV's value of 2.51 is 30.7% above this industry median. Based on the distribution chart, Cosmo NV ranks #571 out of 920 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Cosmo NV has a GF Score™ of 79/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Cosmo NV's PB Ratio compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Cosmo NV ranks #571 out of 920 companies for PB Ratio. This places Cosmo NV in the lower half of its industry. The industry median PB Ratio is 1.92. Cosmo NV's value of 2.51 is 30.7% above this benchmark. Historically, Cosmo NV's own PB Ratio has ranged from 1.22 to 5.87 over the past decade. While the company's 10-year median is 2.77 vs. the industry median of 1.92, Cosmo NV has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.92, based on 920 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cosmo NV's current PB Ratio of 2.51 is 30.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Cosmo NV and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cosmo NV's current PB Ratio is 2.51, which is near median its own 10-year median of 2.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cosmo NV stock overvalued right now?
Based on GuruFocus' analysis, Cosmo NV (LTS:0RGI) is currently considered Significantly Overvalued. The stock's GF Value™ is CHF42.53, compared to a current price of CHF69.72 — trading 63.9% above its estimated fair value. The current PB Ratio is 2.51, which is near median its 10-year median of 2.77 and 30.7% above the Drug Manufacturers industry median of 1.92. Cosmo NV's overall GF Score™ is 79/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Cosmo NV (LTS:0RGI), the current PB Ratio is 2.51 as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cosmo NV (LTS:0RGI) Overvalued in 2026?
Based on GuruFocus' analysis, Cosmo NV stock appears to be overvalued.
The current stock price of CHF69.72 is trading 63.9% above its estimated GF Value™ of CHF42.53.
GuruFocus considers Cosmo NV to be Significantly Overvalued.
Key valuation signals for LTS:0RGI:
PB Ratio: 2.51 (near median its 10-year median of 2.77)
GF Value™: CHF42.53 vs. price of CHF69.72 (63.9% above fair value)
Industry Position: 30.7% above the Drug Manufacturers median (#571 of 920)
No single metric tells the full story. See the LTS:0RGI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cosmo NV is is a life sciences company. The company is focused on MedTech AI, dermatology, gastrointestinal diseases, and contract development and manufacturing (CDMO). The company designs, develops, and manufactures solutions to address critical medical needs. Its technologies are trusted by international pharmaceutical and MedTech companies and reach patients and healthcare providers around the world. The product pipeline includes Eleview, GI Genius, Winlevi, Lialda, Uceris, and others.
79GF Score
Get the complete analysis for LTS:0RGI
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0RGI has been successfully added to your 
